The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 23121096 |
86 |
Ion channels as therapeutic targets: a drug discovery perspective. |
Pfizer |
| 17483457 |
58 |
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. |
Abbott Laboratories |
| 21634377 |
73 |
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. |
Amgen |
| 20965738 |
78 |
Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain. |
Abbott Laboratories |
| 20855211 |
91 |
Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. |
Abbott Laboratories |
| 18501613 |
31 |
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. |
Abbott Laboratories |
| 28629594 |
55 |
The discovery of benzoxazine sulfonamide inhibitors of Na |
Amgen |
Search and Browse
